- Disease: Post-COVID-19
- Study type: Randomised Clinical Trial, Treatment
- Study type descriptors: Interventional
- Objective: To assess the safety and neutralising activity of one dose of AZD3152/Sipavibart compared with one dose of placebo in adults with immunocompromised conditions. Additionally, the study aims to evaluate the efficacy of AZD3152/Sipavibart in reducing the severity of a COVID-19 infection in this population
- Number of participants enrolled: 116
- Study enrolling from to
Study Data
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- AZD3152/Sipavibart
External Links
Other information
Funders/Sponsors:
- AstraZeneca
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to